Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
ZODL founder: The ZEC vulnerability is not a flaw in the underlying cryptography or the proof generation engine

ZODL founder: The ZEC vulnerability is not a flaw in the underlying cryptography or the proof generation engine

金色财经金色财经2026/06/05 04:42
Show original
```htmlJinse Finance reported that on June 5, ZEC suffered a 30% drop due to the unlimited forgery vulnerability in the Orchard pool. Josh Swihart, founder of ZODL, stated that the Orchard vulnerability exists in one of its rules, which was written too loosely and allowed false information to be accepted and still pass verification. As a result, the engine might mistakenly consider fake transactions to be valid. In fact, someone may have forged ZEC in the Orchard transaction pool. This is a flaw in the handwritten rules, not an issue with the underlying cryptography or the proof-generating engine. The question is how to ensure such vulnerabilities do not happen again, and the best answer is formal verification. Tachyon is currently being built using formal verification, with a more concise and unified rulebook. Compared to Orchard, there are fewer special cases and complex details, meaning the entire rulebook can be perfectly verified mathematically. Several teams are already working on formally verifying Orchard's existing circuits. If verification is successful, launching a second Orchard pool in the near term may be the best solution before Tachyon. While Tachyon is more streamlined, a formally verified Orchard pool can serve as an effective transitional measure.```
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage